Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 5, 2010, Pages 2307-2312

  Jiang, Jianxiong ^a   Ganesh, Thota ^b   Du, Yuhong ^a,b   Thepchatri, Pahk ^b   Rojas, Asheebo ^a   Lewis, Iestyn ^a,b   Kurtkaya, Serdar ^b   Li, An ^a,b   Qui, Min ^a,b   Serrano, Geidy ^a   Shaw, Renee ^a   Sun, Aiming ^b   Dingledine, Ray ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Excitotoxicity; Neuronal injury; Prostaglandin E2; Time resolved fluorescence resonance energy transfer; Ultra high throughput screening

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; NANOPARTICLE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; THIOPHENE;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; CELL DAMAGE; CELL LINE; CONTROLLED STUDY; EMBRYO; EXCITOTOXICITY; HIGH THROUGHPUT SCREENING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; BIOSENSING TECHNIQUES; CYCLIC AMP; DINOPROSTONE; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIPPOCAMPUS; NANOPARTICLES; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 76649098560     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909310107     Document Type: Article

References (30)

1. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317-2321.
2. Marcheselli VL, Bazan NG (1996) Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem 271:24794-24799.
3. McCullough L, et al. (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24:257-268.
4. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K (2005) Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 57:758-761.
5. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755.
6. Nakayama M, et al. (1998) Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 95:10954-10959.
7. Iadecola C, et al. (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98:1294-1299.
8. Kawano T, et al. (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229.
9. Yang H, Zhang J, Breyer RM, Chen C (2009) Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 108:295-304.
10. Houchen CW, Sturmoski MA, Anant S, Breyer RM, Stenson WF (2003) Prosurvival and antiapoptotic effects of PGE2 in radiation injury are mediated by EP2 receptor in intestine. Am J Physiol Gastrointest Liver Physiol 284:G490-G498.
11. Paralkar VM, et al. (2003) An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 100:6736-6740.
12. Vukicevic S, et al. (2006) Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure. Kidney Int 70:1099-1106.
13. Liang X, et al. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in amodel ofAlzheimer's disease. JNeurosci 25:10180-10187.
14. Liang X, et al. (2008) The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 64:304-314.
15. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
16. Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
17. Jarvis RA, Patrick EA (1973) Clustering using a similarity measure based on shared nearest neighbors. IEEE Trans Comput 22:1025-1034.
18. Richon A (2000) LeadScope: data visualization for large volumes of chemical and biological screening data. J Mol Graph Model 18:76-79.
19. Coan KE, Shoichet BK (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130:9606-9612.
20. McGovern SL, Caselli E, Grigorieff N, Shoichet BK (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45:1712-1722.
21. FangY, Li G, FerrieAM(2007) Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. J Pharmacol Toxicol Methods 55:314-322.
22. Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5 (Suppl):1039-1042.
23. Concannon CG, et al. (2008) NMDA receptor-mediated excitotoxic neuronal apoptosis in vitro and in vivo occurs in an ER stress and PUMA independent manner. J Neurochem 105:891-903.
24. Lerea LS, et al. (1997) Prostaglandin F2alpha is required for NMDA receptor-mediated induction of c-fos mRNA in dentate gyrus neurons. J Neurosci 17:117-124.
25. Carlson NG, et al. (2009) Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation 6:5.
26. Duffy EM, JorgensenWL(2000) Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 122:2878-2888.
27. Takadera T, Ohyashiki T (2006) Prostaglandin E2 deteriorates N-methyl-D-aspartate receptor-mediated cytotoxicity possibly by activating EP2 receptors in cultured cortical neurons. Life Sci 78:1878-1883.
28. Akaike A, et al. (1994) Prostaglandin E2 protects cultured cortical neurons against Nmethyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 663:237-243.
29. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690.
30. Cimino PJ, Keene CD, Breyer RM, Montine KS, Montine TJ (2008) Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem 15:1863-1869.